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Retrospective Review of Paediatric Rheumatic Mitral Valve Repairs and 
Replacements Done at Red Cross War Memorial Children’s Hospital 
(RCWMCH) Over a Decade 
Alfred Mureko, Justin Batcheller, Melinda Eller, Martina Northrup-Lyons, Paul Human, 
Johan Brink, John Hewitson, Peter Zilla 
Abstract 
Objectives: Rheumatic heart disease remains a significant cause of morbidity and 
mortality and it is the leading cause of acquired paediatric cardiac disease in the 
developing world. The aim of this study was to understand the burden of rheumatic 
heart disease and to review the surgical management of rheumatic mitral valve 
disease at our institution.  
Methods: We retrospectively reviewed 76 consecutive patients who underwent 
mitral valve surgery for rheumatic heart disease between 1998 and 2010. The 
results and follow-up were reviewed, where death and reoperation were the primary 
endpoints. The follow up included a review of the latest information from the 
patients’ medical records and telephonic interviews or home visits. 
Results:  A 91% follow up was achieved over a median follow up period of 7.4 
years (range 0.1-15.2 years). The mean age at surgery was 10.7 years (SD +- 2.7 
years). The females constituted 66% and males 34%. Mitral valve repairs were 
performed in 64% of patients and of the 64% repairs, 0.06% only had 
commissurotomies. Replacements were performed in 36% of patients. All mitral 
valve replacements were mechanical prostheses. The actuarial freedom from 
reoperation for repairs was 83% (+-2.2) and 66% (+-3.4) at 5 and 10 years and for 
replacements was 87% (+-4.8) and 87%(+-4.8) respectively (p=0.27). Actuarial 
freedom from embolic cerebrovascular accidents in the repair group at both 5 and 
10 years was 100%, compared to 90.2% (+-6.6) and 79% (+-12.0) for the 
replacement group at 5 and 10 years respectively (p=0.02). Actuarial freedom from 
death at 5 and 10 years for children over 12.8 years was 77.7% (+-9.9) and 69.1% 
(+-12.0) respectively, compared to 93.6% (+-3.6) and 93.6% (+-3.6) for children 
under 12.8 years (p=0.03). No statistical significant difference was noted in freedom 
from valve related failure and death between repairs and replacements. 
Conclusions: There was no significant difference in survival between mitral valve 
repairs and replacements. There was surprisingly worse survival among children 
who were above 12.8 years at time of the surgery.  
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Chapter 1     
Introduction and literature review 
                      
Introduction 
 Acute rheumatic fever is a complication of repeated untreated Group-A 
streptococcal pharyngitis, which predominantly affect young children and teenagers 
1. Untreated acute rheumatic fever and its repeated attacks results in a chronic 
inflammatory process, which causes damage to the heart valves and this is referred 
to as rheumatic heart disease. Rheumatic heart disease is preventable by 
prolonged penicillin prophylaxis in all patients who had presented with an acute 
rheumatic fever attack 1-3. Rheumatic heart disease is still a significant cause of 
morbidity and mortality among children in the 21st century in the developing world 4 
5. In the early part of the last century before widespread antibiotic availability there 
was a great decline in the incidence and prevalence of acute rheumatic fever in the 
developed world. However, the same has not been seen in sub-Saharan Africa, 
where acute rheumatic fever and its dreaded sequelae of rheumatic heart disease 
still confers a significant burden of disease 2, 5.  
Objectives   
 To determine the burden of rheumatic heart disease globally and specifically 
in the developing world. 
 To identify the surgical management of rheumatic mitral valve disease. 
 To describe the incidence of rheumatic mitral valve repairs and the success 
rates. 
 To understand the progressive nature of rheumatic heart disease and its 
impact on mitral valve repair. 
 To clarify the role of secondary prophylaxis in prevention of further rheumatic 
fever infections 
 To determine the optimal choice of prosthesis in paediatric mitral valve 
replacement and associated complications. 
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Literature search strategy   
The literature search was undertaken using Pubmed and Google scholar under the 
following keyword searches: “Rheumatic heart disease”; “Paediatric rheumatic mitral 
valve surgery”; “Rheumatic mitral valve repair in children”.  
The following journal databases were also searched: 
 European Journal of Cardiothoracic Surgery 
 The Journal of Heart Valve Disease 
 The New England Journal of Medicine 
Another important source of literature was the reference lists of pertinent journal 
articles. 
 
The literature review 
Epidemiology of rheumatic heart disease 
 It is estimated that 15 million people are affected by rheumatic heart disease 
worldwide.6 This estimate is however believed to be a gross under-estimation 
because a significant number of people in sub-saharan Africa are harbouring 
subclinical RHD as shown by Remenyi et al and by recent echocardiographic 
surveys done in Mozambique, Uganda and Senegal 2, 7-10. 
Carapetis et al. in 2005 estimated the global incidence of acute rheumatic fever 
(ARF) in children between 5-14 years to be more than 336 000 cases. They 
estimated the annual number of acute rheumatic fever cases in all ages at more 
than 471 000 cases. They further estimated that over 2·4 million children aged 5–14 
years are affected with rheumatic heart disease. Extrapolating this to all age groups, 
they estimate that there are 15·6–19·6 million people living with rheumatic heart 
disease. 79% of all rheumatic heart disease cases in the studies came from less 
developed countries. Their estimates correspond to all age prevalence rates in less 
developed countries ranging from 2·5 to 3·2 cases per 1000 6.  
Marijon et al. 9 reported that comprehensive echocardiographic screening identified 
approximately 10 times as many children with rheumatic heart disease as were 
identified by the traditional strategy of clinical screening with echocardiographic 
confirmation. In Marijon’s report, rheumatic heart disease was defined by the 
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presence of any definite evidence of mitral- or aortic-valve regurgitation seen in two 
planes by Doppler echocardiography, accompanied by at least two of the following 
three morphologic abnormalities of the regurgitant valve: restricted leaflet mobility, 
focal or generalized valvular thickening, and abnormal subvalvular thickening. For a 
definite diagnosis of rheumatic heart disease, these features had to be identified 
concordantly by each of the echocardiographers, all of whom were experienced in 
the diagnosis and treatment of rheumatic heart disease 9.  
 There has been a decline in the incidence of rheumatic fever in the Western world 
but this has not been seen in sub-Saharan Africa. The incidence decline in the 
Western world is not entirely clear but it is probably related to the better socio-
economic conditions, such as better sanitation, less overcrowding, and overall 
better living conditions, all of which result in a reduction in infectious diseases in 
general and streptococcal infections in particular 5. 
Carapetis et al. described rheumatic fever as a disease of poverty and that it is in 
many ways the epitome of diseases of poverty and social injustice11. There is great 
underreporting of acute rheumatic fever incidence and prevalence in sub-Saharan 
Africa. Underreporting has always been a big problem in South Africa despite acute 
rheumatic fever being declared a notifiable disease in the 1980’s. This was shown 
by Ngudi et al. in 2006 12.   
As rheumatic heart disease continues to be a major cause of morbidity and mortality 
in developing nations, particularly in the young economically and socially active 
sector of the population, the availability of epidemiological data is certain to aid with 
case finding, delivery of effective primary and secondary prevention, and adequate 
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Features of acute rheumatic fever and rheumatic heart disease 
Acute rheumatic fever (ARF) is a complication of an untreated Group-A 
streptococcal pharyngitis, which predominantly affect young children and 
teenagers1. Molecular mimicry explains the triggering of ARF, but an intense and 
sustained inflammation is needed to cause the sequelae of chronic rheumatic heart 
disease 13. This interaction is an autoimmune response, in which genetic factors 
affect the individual's susceptibility. 
ARF is mediated by humoral and cellular autoimmune responses that occur as 
delayed sequelae of Streptococcus pyogenes infection. Environmental factors such 
as poor socio-economic circumstances and limited access to medical care partially 
explain susceptibility, but individual factors are known to play a role. Only a small 
proportion of patients develop the full complement of symptoms 13. 
 
Acute rheumatic fever usually occurs 3 weeks following a group A streptococcal 
pharyngitis and around half of patients with ARF present with cardiac inflammation 
mainly involving the valvular endocardium 14. It usually manifest as a systematic 
disease, and then cardiac symptoms may become prominent depending on the 
severity of the carditis. The carditis always present as a pancarditis, affecting all the 
anatomic layers of the heart; the endocardium, myocardium and pericardium. 
Valvular incompetence is typically the lesion of acute rheumatic fever with carditis 
and is the forerunner of the long-term sequelae of this disease, known as rheumatic 
heart disease 5. It is worth noting that not all ARF carditis sustain significant valvar 
damage to progress to MR.  
The microscopic hallmark feature of ARF is the Aschoff bodies, which are 
histiocytes aligned in palisades around fibrinoid necrosis, giving a particular 
appearance. submiliary nodules located in the myocardium usually in close 
proximity to small blood vessels. The typical macroscopic characteristics of the ARF 
endocarditis are very small, warty, firmly adherent vegetations of deposited platelets 
along the zone of contact of valve cusps.  
The intra-operative (macroscopic) findings in acute rheumatic fever associated 
mitral valve incompetence are usually chordal rupture or elongation and annular 
dilatation. Often the whole heart is inflamed. On the other hand, the typical intra-
operative findings in RHD mitral valve incompetence are; thickened retracted 
leaflets, elongated or ruptured chordi with associated leaflet prolapsed or 
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alternatively restricted valve mobility due to chordal tethering (Type 3B according to 
the Carpentier Classification of mitral leaflet motion). Chronic rheumatic heart 
disease presenting with predominant mitral stenosis tend to exhibit the following 
macroscopic features; thickened leaflets with some degree of calcification, immobile 
leaflets, commissural fusion and shortened sub-mitral apparatus with variable 
chordal fusion 5 14.   
Clinical presentation 
ARF is a systemic illness of few sequelea first time but subsequent attacks cause a 
much higher incidence of severe carditis and then MR becomes the hallmark. ARF 
is marked by fever and joint pains, and is diagnosed by the Ducket-Jones criteria. 
Acute rheumatic fever classically presents as acute mitral incompetence and it is 
only after repeated acute rheumatic fever attacks and progressive fibrosis and 
usually in the 3rd decade of life when rheumatic mitral stenosis is seen. This has 
been shown in previous paediatric rheumatic mitral studies by Kalangos et al from 
Switzerland and by Hillman et al from the USA3, 15  
However, a recent Ethiopian paediatric (age range 3-15 years) rheumatic mitral 
study by Tadele et al had shown a significant prevalence of rheumatic mitral 
stenosis in the paediatric age group 16. The Ethiopian study observed a high 
prevalence of mitral stenosis in patients between the ages 6–10 years and the 
overall prevalence of mitral stenosis in paediatric patients was 34.5% while the 
overall prevalence of severe mitral stenosis, defined as a valve area of less than 1.0 
cm2, was 18.1%.16 This high prevalence of paediatric mitral stenosis in Ethiopia is 
probably a reflection of the state of the disease in most parts of sub-Saharan Africa, 
where the epidemiology is not well defined. This unprecedented finding by Tadele et 
al is certainly related to the persistence of poor socio-economic conditions in sub-
Saharan Africa and the associated recurrent acute rheumatic fever attacks coupled 
with inadequate secondary penicillin prophylaxis. Late presentation to healthcare 
facilities has been identified as one of the factors that increase the burden of 
rheumatic heart disease in sub-Saharan Africa. This was clearly shown by Sliwa et 
al. in the “Heart of Soweto” study, where the majority of patients presented with 
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Primary prevention of rheumatic fever 
Researchers agree that the reason why there has been a decrease in the incidence 
of ARF in the developed world is mainly a result of improved socio-economic 
dynamics. As such, the first emphasis in preventing ARF infections in the high 
incidence areas is to address the living standards within the poor communities. 
Addressing overcrowding, poverty, poor sanitation and access to healthcare should 
form the basis of primary prevention of ARF infections 18, 14. 
 It is clearly evident that the socio-economic conditions in the developing world are 
not about to change drastically within the near future. Looking at RSA, one can 
appreciate that the poverty gap remains a big problem as the number of informal 
settlements are still on the rise 19. With the persistence of the poor socio-economic 
conditions in our society it is imperative to focus on other means of primary 
prevention.  
This relies on the eradication of group-A streptococcal throat carriage. Early 
diagnosis and treatment of sore throat with penicillin is widely advocated as an 
effective means of preventing ARF infections. This mode of primary prevention is 
often challenging and has been largely neglected in the developing countries 14 18 20.  
Clinically, it can be difficult to diagnose group-A streptococcal pharyngitis if the 
disease is not borne in mind and without microbiological confirmation. The disease 
should always be part of the differential diagnoses in a patient with fever and a sore 
throat. Some developing countries do not have the necessary laboratory analysis for 
confirming the disease 21. A systematic review by Robertson concluded that giving 
antibiotics to patients with sore throats and symptoms suggestive of a streptococcal 
infection reduces the risk of rheumatic fever by 70%. Intramuscular penicillin 
reduces the risk further, to 80% 22. Therefore, in communities where ARF is 
prevalent all young people aged 5-15 years with a sore throat should be considered 
to have a streptococcal infection and be treated with an antibiotic 23 20.   
With the discovery of a vaccine against measles, the world has seen a massive 
decline in the incidence of measles. Hence, the development of a vaccine against 
streptococcal throat infections should be the ultimate weapon in the primary 
prevention of acute rheumatic fever. One of the constraints hampering the 
development of the vaccine is the presence of multiple strains of Group A 
streptococci. The vaccines are developed in the “first world” where the strains are 
different and as such the vaccines are ineffective where they are needed most. A 
 
Alfred Mureko Page 16 
 
number of vaccines are in development, and a safe and effective vaccine may well 
be available within one or two decades11. 
Secondary prevention of rheumatic heart disease 
It is conceivable that the failure in primary prevention leads to the development of 
acute rheumatic fever but there is still a chance of preventing the development of 
chronic rheumatic heart disease. The prevention of further recurrent attacks of acute 
rheumatic fever is the only way to prevent rheumatic heart disease. This is known 
as secondary prevention and it is deemed a more cost-effective and attainable goal 
than primary prevention 23 5. Penicillin remains the antibiotic of choice. Intramuscular 
penicillin is preferred over the oral route as it is more effective and results in better 
compliance 23 21. The duration of secondary prophylaxis depends on the patients’ 
age, the date of their last attack, and most importantly the presence and severity of 
rheumatic heart disease 23 14. The WHO secondary prevention guidelines are as 
follows 23:  
 
 Patients without proven carditis; Penicillin for 5 years after the last 
attack or until 18 years of age (whichever is longer) 
 
 Patients with carditis; Penicillin for 10 years after the last attack, or 
at least until 25 years of age (whichever is longer) 
 
 Patients with more severe valvular disease; Lifelong penicillin  
 
 Patients after valve surgery; Lifelong penicillin. 
 
 
For over 20 years, the World Health Organization has recommended secondary 
prophylaxis to be delivered within a coordinated program using a registry of 
patients, as the first priority for the control of rheumatic heart disease 11 18. For a 
long time most developing countries did not have effective secondary prevention 
programmes and hopefully with the advent of the Rheumatic Heart Disease Global 
Registry (REMEDY) programme there will be increased accessibility to secondary 
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Surgical management of rheumatic heart disease 
The surgical options for rheumatic mitral valve disease range from simple closed 
mitral valvotomy to complex mitral valve repair and finally valve replacement. Mitral 
valve repair for rheumatic heart disease is commonly believed to yield inferior 
results in contrast to degenerative aetiology. This is a natural consequence of the 
progressive nature of the rheumatic process, which continues to distort the valve 
apparatus even beyond a successful repair 24 25. This attrition in rheumatic mitral 
valve repair is further worsened by repeated acute rheumatic fever attacks 10, 15, 24, 26-
32. The WHO now recommends life-long prophylaxis in patients with severe valve 
disease or who have had valve surgery 23 24. The choice of the surgical procedure is 
dictated by the valve lesion, availability of resources and surgical skills.  
 
Pure mitral incompetence: 
A. Mitral valve repair: Pure isolated mitral incompetence is often the manifestation of 
acute rheumatic fever with carditis and it is also the hallmark of chronic rheumatic 
heart disease. This is the area where Carpentier and others spent a lot of time in the 
1970s trying to perfect mitral valve coaptation and abolishing mitral incompetence. 
Rheumatic mitral valve repair is technically more difficult than degenerative repair 
and the results are also inferior. It is worth mentioning that in good hands a perfect 
and durable rheumatic valve repair is possible and has been shown in multiple 
studies 15 37 38 39 40. Mitral valve repair is favoured for various reasons; it preserves 
the LV systolic function through the preservation of the sub-mitral apparatus, it 
avoids the attendant risks of anticoagulation associated with mechanical mitral valve 
prostheses, and it also has lower 30-day mortality and better overall survival when 
compared to replacements.28, 38, 41, 42 
 Modern mitral valve repair is based on the pioneer work of Carpentier 43 and the 
principles that he described in “the French correction”. 
                           Elements of the French correction: 
1. Functional approach to valve disease based on leaflet mobility 
 Class I: Normal leaflet mobility, annular dilatation 
Class II: Excessive leaflet mobility due to either chordal rupture, elongation, 
pappilary muscle rupture 
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Class III: Restricted leaflet mobility due to either shortened and thickened 
chordae or fused chordae or thickened immobile leaflets; or ventricular 
dilatation with restricted chordal motion. 
2. Adequate valve exposure 
The mitral valve can be approached via different accesses; 
 Horizontal left atriotomy; this is the most commonly used incision, it 
involves developing the inter-atrial groove (Waterston’s groove) 
between the back of the right atrium (RA) and the roof of the left 
atrium (LA). The LA is then incised in its roof. 
 Superior trans-septal approach; this incision is over the roof of the LA 
and the inter-atrial septum cephalad from the fossa ovalis. It offers 
excellent exposure in small LA. 
 Bi-atrial approach; this approach is uncommon and it involves a 
vertical right atriotomy and vertical trans-septal incision. It risks 
damage to the bundle of His, tricuspid annulus and atrioventricular 
septum.  
3. Valve analysis 
Current valve repair guidelines stipulate the use of intra-operative trans 
oesophageal echocardiogram (TOE) to assess the valve intra-operatively 
before and immediately after coming off cardiopulmonary bypass 44. The 
pre-operative TOE findings guide the surgeon when performing the surgical 
valve analysis. The scallops on the posterior mitral valve are used to denote 
P1-P3 descriptors and the corresponding anterior mitral valve segments are 
denoted as A1-A3. All the prolapsed components and altered chordae 
should be identified and as well as fused commisures and retracted leaflets. 
A saline flush test is performed to test for incompetence prior to commencing 
the valve repair.  
4. Ring annuloplasty 
It is well described and accepted that some degree of mitral annular 
dilatation usually accompany mitral valve incompetence. As such, mitral 
valve repair is usually not complete until an annuloplasty has been 
performed in order to stabilise the mitral valve complex. The options for 
mitral annuloplasty are; suture annuloplasty, partial ring annuloplasty and 
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complete ring annuloplasty. Remodelling of the mitral valve annulus is only 
possible with moulded rings, which assumes the natural mitral annular 
configuration. Complete ring annuloplasty is the superior annuloplasty 
technique. Suture annuloplasty leave a round annulus, which is less 
functional and has been largely abandoned due to its poor results 29 28 45 42. 
In the modern era, partial rings and suture annuloplasties are only limited to 
children with diminutive annulus unable to accommodate complete rings.  
5. Repair of anterior leaflet prolapse 
The options are; 
 triangular leaflet resection  
 chordal transfer 
 chordal transposition 
  chordal shortening 
 neo-chordal insertion using PTFE (Goretex) suture  
6. Repair of posterior leaflet prolapsed 
 The options are; 
 quadrangular leaflet resection 
 neo-chordal insertion using PTFE (Goretex) suture  
 
 
7. Repair of restricted leaflet motion 
 Thickened calcified leaflets are decalcified and excessive fibrotic 
tissue shaved off in order to improve mobility 
 Retracted leaflet is addressed by elongation of the leaflet performed 
with the use of gluteraldehyde treated autologous pericardium 
8. Intra-operative evaluation of the repair 
 Saline flush test by the surgeon 
 Most importantly, TOE assessment has become an essential part of 
the guidelines for mitral valve repair assessment.   
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9. Repairing all repairable valves 
All cases of mitral valve disease should be approached with repair in mind. 
Indications for mitral valve repair are based upon the lesion rather than the age, 
cause of the disease and patient condition. However, the younger the patient, the 
more urgent are the indications for valve reconstruction 43. According to the latest 
American Heart Association valve guidelines, it is a class I indication to attempt 
repair of all valves; mitral valve repair is recommended in preference to MVR when 
surgical treatment is indicated for patients with chronic severe primary MR involving 
the anterior leaflet or both leaflets when a successful and durable repair can be 
accomplished 44.  
  
Pure mitral stenosis:  
A. Percutaneous balloon mitral valvoplasy: The cardiologists usually asses the 
valve’s favourability for percutaneous valvotomy. The absence of MR, absence of 
LA clot and a Wilkin’s score of less than 8 are all the parameters used in identifying 
patients favourable for this procedure. The Wilkin’s score is a valve assessment 
score focusing on leaflet mobility, thickness and calcification, and submitral disease 
33. Adequate leaflet mobility, lack of calcification and minimal sub-mitral disease are 
the favourable elements to look for.  
B. Closed mitral valvotomy: This procedure is currently limited to the poor resource 
constrained units, where balloon valvuloplasty is unavailable. It is performed via a 
left anterolateral thoracotomy without the use of cardiopulmonary bypass. It involves 
the use of Tubbs dilators introduced via the left ventricular apex to crack open the 
stenotic mitral valve to a pre-set diameter while a finger introduced via the left 
auricle palpates the valve. In other words, this procedure is performed without direct 
vision of the mitral valve.  
C. Open mitral valvotomy: This procedure is performed via a median sternotomy 
with cardiopulmonary bypass. It is performed under direct vision and it primarily 
involves commisurotomy of the fused commisures. Surgeons might also opt to 
shave the thickened leaflets to allow better leaflet mobility. The presence of severe 
submitral disease, which requires splitting of fused papillary muscles makes 
valvotomy less successful 34 5 35.  
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D. Mitral valve replacement: Pure mitral stenosis is fortunately less common in the 
paediatric population but certainly more common in sub-Saharan Africa than the 
developed world 16. There is a choice between bioprosthetic and mechanical valves. 
The bioprosthetic valves in the paediatric population degenerate rapidly and as such 
they are contra-indicated 36. On the other hand, the implantation of mechanical 
prostheses in children is complicated by the risk of thrombo-embolism and the 
attendant drawbacks of anticoagulation, such as catastrophic bleeds with INR 
toxicity. The developing world is faced with issues of inaccessible health facilities 
and this means that patients with mechanical valves could go for weeks or longer 
without their anticoagulants or without surveillance of their INRs. This has been 
seen time and time again in our setting. 
 
Mixed mitral incompetence and stenosis  
This group of patients have complex disease, which makes mitral valve repair a 
great challenge37 46. Lesions of this nature, call for the application of surgical 
techniques used in both mitral valvotomy and repair in order to achieve a successful 
outcome. 
 
Timing of surgery 
 The surgical management of rheumatic mitral valve disease is in accordance with 
the American and European guidelines on valvular heart disease management. The 
guideline recommendations on surgical intervention are mainly based on the 
symptoms of the patients and enlarging left ventricular dimensions. Deterioration of 
the left ventricular function is also an important indicator for surgical management of 
patients with mitral incompetence. Chronic mitral regurgitation has an insidious 
course, which results in volume overload of the left ventricle and irreversible systolic 
dysfunction may occur if surgical correction is delayed too long. Thus, serial 
echocardiographic follow up is of vital importance in order to identify the tipping 
point at which the LV function and dimensions deteriorate to meet the indications 
(LVESD>40mm) for surgical intervention 1 44 47. Another important indicator for 
surgery that has been recently added to the general guidelines for mitral valve 
repair is as follow; mitral valve repair is indicated in asymptomatic patients with 
moderate to severe mitral incompetence, preserved LV function and dimensions 
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provided there is a high likelihood (>90%) of a successful repair 44. This guideline is 
applicable in patients with degenerative mitral disease but the predictability of mitral 
repair in rheumatic valve disease is problematic and therefore difficult to 
recommend in patients with rheumatic mitral incompetence.  
  
Challenges in rheumatic MV repair 
Extensive fibrosis and calcification of the sub-valvar apparatus, commissures, and 
annulus can hamper the success of valve repair 35 27. Inevitably in mitral vave repair, 
diseased tissue is left behind, and despite good anatomic valve mobility 
intraoperatively, some hemodynamic obstruction persists and can progress to 
clinically important mitral stenosis over time. This phenomenon has been described 
by Carpentier’s group and was related to progressive fibrosis, which usually 
parallels the degree of preoperative valve fibrosis 48. The lack of secondary 
prevention programmes translates into repeated acute rheumatic fever infections 
and accelerated attrition of repaired mitral valves. 
 
In order to circumvent the progressive nature of the disease, El Oumerie et al.49, 
reported on their series of aggressive excision of the diseased leaflet tissue and of 
the supporting fused sub-valvular apparatus to remove all valvular tissue that is 
affected by rheumatic disease. This required an extensive reconstruction using 
pericardial patches, artificial chordae, tricuspid autograft and or mitral homografts in 
selected cases 49. This aggressive approach extends the spectrum of mitral valve 
repair in RHD 49 50 35, but a high level of surgical expertise is required. 
 
Predictors of poor outcome in mitral valve repair 
The major predictors of outcome can be classified according to timing of surgery, 
intra-operative findings and repair technique, and lastly the accessibility to 
secondary prevention. Sometimes, valve surgery is the only management option in 
children who present with acute rheumatic fever and intractable congestive cardiac 
failure. The timing of surgery is significant because the presence of active rheumatic 
carditis at the time of surgery is an important predictor of valve failure and the need 
for reoperation 51.  Younger age at surgery is also a significant factor because of the 
prolonged risk of repeated episodes of ARF infections, especially in the developing 
countries, where secondary prevention is often sub-optimal46 49 52.  
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 Other important predictors of poor outcome include; the presence of mixed mitral 
stenosis and insufficiency, leaflet retraction, severe subvalvar disease and bi-leaflet 
prolapse 27 53 46 49 37 5 34 40.   
 
Summary of the literature  
Acute rheumatic fever is a complication of an untreated Group-A streptococcal 
pharyngitis, which predominantly affects young children and teenagers.1 Untreated 
acute rheumatic fever and its repeated attacks results in a chronic inflammatory 
process, which causes damage to the heart valves and this is referred to as 
rheumatic heart disease. Rheumatic heart disease is preventable by prolonged 
penicillin prophylaxis in all patients who had presented with an acute rheumatic 
fever attack1-3. Rheumatic heart disease is still a significant cause of morbidity and 
mortality among children in the 21st century in the developing world 6 5 2. In the latter 
part of the last century there has been a great decline in the incidence and 
prevalence of acute rheumatic fever in the developed world. However, the same has 
not been demonstrated in sub-Saharan Africa, where acute rheumatic fever and its 
dreaded sequelae of rheumatic heart disease still confer a significant burden of 
disease2, 5. In sub-Saharan Africa and the rest of the developing world there is a 
persistence of factors, which allow acute rheumatic fever to flourish. These factors 
are all associated with poverty and include overcrowding, poor sanitation, 
inaccessible healthcare systems and the erratic availability of secondary prevention 
measures in the form of penicillin prophylaxis 1, 17. It is projected that 15 million 
people are affected by rheumatic heart disease worldwide6 .This projection is 
however believed to be a gross under-estimation since a significant number of 
people in sub-saharan Africa harbour subclinical RHD as reported by Remenyi et al 
and by recent echocardiographic surveys conducted in Mozambique, Uganda and 
Senegal.2, 7-10.  
Rheumatic heart disease typically affects the mitral valve before the other heart 
valves and as a result there is predominantly a higher prevalence of rheumatic 
mitral valve disease in paediatrics3. Acute rheumatic fever classically presents as 
acute mitral incompetence and it is only after repeated acute rheumatic fever 
attacks and usually in the 3rd decade of life, when rheumatic mitral stenosis is first 
observed. This has been shown in previous paediatric rheumatic mitral studies by 
Kalangos et al (2012,Switzerland) and by Hillman et al (2012,USA)3,15. However, a 
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recent Ethiopian paediatric (age range 4-15 years) rheumatic mitral study by Tadele 
et al. had shown a significant prevalence of rheumatic mitral stenosis in the 
paediatric age group16. The Ethiopian study observed a high prevalence of mitral 
stenosis in patients between the ages 6–10 years (26.5%) with an overall 
prevalence of mitral stenosis in paediatrics of 34.5%, while the overall prevalence of 
severe mitral stenosis, defined as a valve area of less than 1.0 cm2, was 18.1%16. 
This high prevalence of paediatric mitral stenosis in Ethiopia is probably a reflection 
of the state of the disease in most parts of sub-Saharan Africa, where the 
epidemiology is not well defined. This unprecedented finding by Tadele et al. is 
certainly related to the persistence of poor socio-economic conditions in sub-
Saharan Africa and the associated recurrent acute rheumatic fever attacks coupled 
with inadequate secondary penicillin prophylaxis. Late presentation to healthcare 
facilities has been identified as one of the factor, which increases the burden of 
rheumatic heart disease in sub-Saharan Africa. This was clearly shown by Sliwa et 
al in the “Heart of Soweto” study, where the majority of patients presented with 
advanced cardiac disease and where the predominant primary diagnosis was heart 
failure. Sliwa et al. also showed an increased burden of newly diagnosed rheumatic 
heart disease but no single case of acute rheumatic fever was diagnosed and this 
was thought to be a result of under-estimation of acute rheumatic fever by parents 
and first-line healthcare practitioners 17.  
It is widely accepted that rheumatic mitral valve repair is the procedure of choice in 
both developed and developing worlds 50 49 38 29 24, 34, 35, 39. The attrition in rheumatic 
mitral valve repair is largely due to the progressive nature of RHD, and due to 
repeat acute rheumatic fever attacks.10, 15, 24, 26-32 Mitral valve replacement with 
mechanical valves in paediatrics will always remain a challenge with regards to 
anticoagulation monitoring.  Antunes’ study on mitral valve replacement in 
Johannesburg in the 1980’s clearly demonstrated that mechanical valves have a 
high incidence of thromboembolic complications because of poor anticoagulation 
adherence. Bioprosthetic mitral valves are a good option for women of childbearing 
age but they degenerate much faster in the younger active patients and almost 
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Identification of need for further research   
It is undisputed that mitral tissue prosthesis in the young deteriorates faster due to 
the young patient’s active haemodynamics 55-57. As such, it has become common 
practise at RCWMCH to implant an otherwise undesirable mechanical prosthesis in 
children.  Future research needs to focus on the exact morphology of the repaired 
mitral valves in order to identify the risk factors associated with poor repair 
outcomes as has been shown in the adult cohort at Groote Schuur hospital by 
Geldenhuys et al 59 .The follow up of all paediatric surgery patients registered under 
the REMEDY database will result in a greater follow up and perhaps a better 
description of the incidence of rheumatic fever re-infections and its impact on the 
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Retrospective Review of Paediatric Rheumatic Mitral Valve Repairs and 
Replacements Done at Red Cross War Memorial Children’s Hospital 
(RCWMCH) Over a Decade 
Alfred Mureko, Justin Batcheller, Melinda Eller, Martina Northrup-Lyons, Paul Human, 
Johan Brink, John Hewitson, Peter Zilla 
Abstract 
Objectives: Rheumatic heart disease remains a significant cause of morbidity and 
mortality and it is the leading cause of acquired paediatric cardiac disease in the 
developing world. The aim of this study was to understand the burden of rheumatic 
heart disease and to review the surgical management of rheumatic mitral valve 
disease at our institution.  
Methods: We retrospectively reviewed 76 consecutive patients who underwent 
mitral valve surgery for rheumatic heart disease between 1998 and 2010. The 
results and follow-up were reviewed, where death and reoperation were the primary 
endpoints. The follow up included a review of the latest information from the 
patients’ medical records and telephonic interviews or home visits. 
Results:  A 91% follow up was achieved over a median follow up period of 7.4 
years (range 0.1-15.2 years). The mean age at surgery was 10.7 years (SD +- 2.7 
years). The females constituted 66% and males 34%. Mitral valve repairs were 
performed in 64% of patients and of the 64% repairs, 0.06% only had 
commissurotomies. Replacements were performed in 36% of patients. All mitral 
valve replacements were mechanical prostheses. The actuarial freedom from 
reoperation for repairs was 83% (+-2.2) and 66% (+-3.4) at 5 and 10 years and for 
replacements was 87% (+-4.8) and 87%(+-4.8) respectively (p=0.27). Actuarial 
freedom from embolic cerebrovascular accidents in the repair group at both 5 and 
10 years was 100%, compared to 90.2% (+-6.6) and 79% (+-12.0) for the 
replacement group at 5 and 10 years respectively (p=0.02). Actuarial freedom from 
death at 5 and 10 years for children over 12.8 years was 77.7% (+-9.9) and 69.1% 
(+-12.0) respectively, compared to 93.6% (+-3.6) and 93.6% (+-3.6) for children 
under 12.8 years (p=0.03). No statistical significant difference was noted in freedom 
from valve related failure and death between repairs and replacements. 
Conclusions: There was no significant difference in survival between mitral valve 
repairs and replacements. There was surprisingly worse survival among children 
who were above 12.8 years at time of the surgery.  
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Introduction 
In South Africa, as seen in other developing nations, we have a significant burden of 
rheumatic heart disease (RHD) and as such we need to have a good understanding 
of this disease to enable us manage our patients optimally. This high burden of 
RHD in South Africa provides an excellent platform for conducting local research, 
which will be most beneficial to our patient population. The paucity of local research 
is probably the reason why we are still waiting for the development of an effective 
vaccine against the local strains of Group- A streptococcus. Having realised the 
need for local research in RHD, we were inspired to contribute. This study aims to 
describe the pathology of acute rheumatic fever (ARF) and rheumatic heart disease 
(RHD). Particular attention will be focused on the surgical management options for 
rheumatic mitral valve disease in our indigent poor population. 
ARF is a complication of an untreated Group-A streptococcal pharyngitis, which 
predominantly affect young children and teenagers.1. Untreated ARF and its 
repeated attacks results in a chronic inflammatory process, which causes damage 
to the heart valves and this is referred to as RHD. Recurrent attacks of ARF, and 
thus progressive RHD, is preventable by prolonged penicillin prophylaxis in all 
patients, who have had an ARF attack1-3. RHD remains a significant cause of 
morbidity and mortality among children in the 21st century in the developing world 18 
6 5. In the early part of the last century before widespread antibiotic availability there 
was a great decline in the incidence and prevalence of acute rheumatic fever in the 
developed world 6, 18. However, the same has not been seen in sub-Saharan Africa, 
where ARF and its sequelae of RHD still constitute a significant burden of disease2, 
5. In sub-Saharan Africa and the rest of the developing world there is a persistence 
of factors, which favours the flourishing of acute rheumatic fever. These factors are 
all associated with poverty and include malnutrition, overcrowding, poor sanitation, 
inaccessible healthcare systems and the erratic availability of secondary prevention 
in the form of penicillin prophylaxis1, 17. It is estimated that 15 million people are 
affected by rheumatic heart disease worldwide.6 This estimate is however believed 
to be a gross under-estimation because there is insufficient data about 
underdeveloped areas; Remenyi et al. showed with echocardiographic surveys in 
Mozambique, Uganda and Senegal that a significant number of people in sub-
Saharan Africa are harbouring subclinical RHD 2, 7-10.  
RHD typically affects the mitral valve before the other heart valves and as a result 
the predominant lesion in children with RHD is mitral valve disease 3. The general 
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systemic features of ARF include fever, sore throat, malaise and etc (Ducket-Jones 
criteria). ARF with significant carditis classically presents as acute mitral 
incompetence and as fibrosis progresses (RHD), usually in the 3rd decade of life we 
start seeing mitral stenosis. This has been shown in previous paediatric rheumatic 
mitral studies by Kalangos from Switzerland and by Hillman from the USA.3, 15 
However, a recent Ethiopian paediatric (age range 3-15) rheumatic mitral study by 
Tadele et al had shown a significant prevalence of rheumatic mitral stenosis in the 
paediatric age group.16. The Ethiopian study observed a high prevalence of mitral 
stenosis in patients between the ages 6–10 years (26.5%) and the overall 
prevalence of mitral stenosis in paediatrics was 34.5% while the overall prevalence 
of severe mitral stenosis, defined as a valve area of less than 1.0 cm2, was 
18.1%.16. This high prevalence of paediatric mitral stenosis in Ethiopia is probably a 
reflection of the state of the disease in most parts of sub-Saharan Africa, where the 
epidemiology is not well defined. This unprecedented finding by Tadele is certainly 
related to the persistence of poor socio-economic conditions in sub-Saharan Africa 
and the associated recurrent acute rheumatic fever attacks coupled with inadequate 
secondary penicillin prophylaxis. Late presentation to healthcare facilities has been 
identified is one of the factors that increases the burden of rheumatic heart disease 
in sub-Saharan Africa. This was shown by Sliwa et al in the “heart of Soweto”, 
where the majority of patients presented with advanced cardiac disease and where 
the predominant primary diagnosis was heart failure. Sliwa also showed an 
increased burden of newly diagnosed RHD but no single case of ARF was 
diagnosed and this was thought to be a result of under-estimation of ARF by 
parents and first-line healthcare practitioners 17.  
It is widely accepted that rheumatic mitral valve repair is the procedure of choice in 
both developed and developing worlds 3824, 29, 39, 43, 45, 50. The attrition in rheumatic 
mitral valve repair is largely due to the progressive nature of RHD and repeat ARF 
attacks.10, 15, 24, 26-32. Mitral valve replacement with mechanical valves in paediatrics 
will always remain a challenge with regards to anticoagulation monitoring. Substitute 
heart valves have major limitations in a third world population. Antunes’ study on 
mitral valve replacement in Johannesburg in the 1980’s demonstrated that 
mechanical valves have a high incidence of thromboembolic complications because 
of poor anticoagulation 36. Bioprosthetic valves have a high failure rate in the young, 
although they are still an acceptable alternative in women of childbearing age 36, 61, 62 
57 
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Patients and methods 
Patients 
The undertaking of the study was approved by the University of Cape Town’s 
Research Committee and by the management of the Red Cross War Memorial 
Children’s Hospital (RCWMCH). Ethical approval was granted by the University’s 
Human Ethics Committee. We retrospectively reviewed 76 consecutive patients who 
underwent first-time single mitral valve surgery for rheumatic heart disease at the 
RCWMCH, Chris Barnard Division of Cardiothoracic Surgery, at the University of 
Cape Town between January 1998 and December 2010. The RCWMCH is one of 
the major referral centres in South Africa and as such we receive a significant 
number of patients from other provinces within the country. The majority of our 
study population (57%) came from within the Western Cape while 41% were 
referred from the Eastern Cape and a further 2% from the Northern Cape Province. 
Patients in our study were predominantly black (76%) and the remainder 24% were 
coloureds (mixed race). This pattern is a reflection of the South African socio-
economic distribution and it is illustrative of the fact that RHD is a disease of 
poverty. 
The mean age at surgery was 10.7 years (SD+-2.7) with an age range of 4 to 17 
years. The females constituted 66% and males 34%. MV repairs (MVrep) were 
performed in 64% of patients and of the 64% repairs, 0.06% only had 
commissurotomies. Replacements (MVR) were performed in 36% of the cohort.  All 
the replacements used mechanical prosthesis. The majority of our patients came 
from poor socio-economic backgrounds associated with malnutrition, overcrowding 
and poor sanitation. 
Surgery 
All procedures were performed via a median sternotomy on cardiopulmonary 
bypass, with aortic and bicaval cannulation at moderate hypothermia (27-32 
degrees Celsius). The left atrium (LA) was usually accessed via the Waterstons 
groove or occasionally trans-septally if a tricuspid annuloplasty (TA) was to be done. 
Mitral valve procedures ranged from simple open mitral vulvotomies to repairs or 
replacements. All the repairs were performed by two of the authors (JB and JH). 
Repairs always included the use of an annuloplasty ring, with the exception of one 
patient in whom a partial suture annuloplasty was done because a suitable ring size 
was not available. The annuloplasty rings used were mostly Biotek (a rigid ring 
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made locally and is a copy of the classical Carpentier ring) in the early 2000s but 
this shifted to the Carpentier/Edwards’ Physio rings in the latter 2000s. We 
employed the various techniques described by Carpentier in achieving competency 
of the mitral valve, including chordal shortening and transfer, splitting of fused 
subvalvar apparatus, leaflet resection and/or augmentation with gluteraldehyde-
treated autologous pericardium and commissurotomies. Chordal replacement using 
PTFE was also used as a mitral repair technique. On completion of the mitral valve 
repair and prior to closing the atium, competence was tested using a 50ml bulb 
syringe to inject saline into the left ventricle to observe coaptation and competence 
of the leaflets. A trans-oesophageal echocardiogram (TOE) was used to assess all 
the repairs intra-operatively once the heart had resumed beating. If the repair was 
suboptimal on TOE, the surgeon would re-establish bypass and attempt to improve 
the repair. If repair was technically unachievable then the valve would be replaced 
with a prostheses.  
 All our mitral valve replacements were with mechanical prostheses (either SJM or 
On-X bileaflet prostheses). The smallest implanted valve was a 21mm SJM and the 
largest was a 29mm SJM. Concomitant procedures, included in our study were 
tricuspid annuloplasty (TA) and MAZE procedure.  The six TAs performed were 
DeVega suture annuloplasties. There was a single MAZE procedure performed for 
Atrial Fibrillation (AF). 
Data collection and post-operative follow-up 
Ethical approval for the study was granted by the University’s Human Ethics 
Committee. Informed consent was obtained from the parents of minors or directly 
from the older patients (>18 years at time of the interview). The patient’s names 
were identified from the operating theater record books, the perfusionists’ pump 
sheets and also from our clinical patient database. The patient’s medical folders 
were then retrieved from the hospital’s medical records department and all the 
pertinent information was entered into an electronic spreadsheet (Excel). 
 All our patients underwent a pre-discharge transthoracic echocardiogram to assess 
valve function, ventricular contractility and to exclude significant pericardial 
effusions. The patients, living within the Cape Town Metropolitan District underwent 
repeat echocardiograms at 6 weeks and 6 months after discharge. However, the 
patients referred from other provinces were followed-up at their respective referring 
hospitals where follow up echocardiogram was not always possible. All mitral valve 
repair patients were placed on 3 months of warfarin therapy in order to allow the 
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annuloplasty ring to endothelialise. The INR target value was between 2 and 3. 
Patients having mitral valve replacements were placed on lifelong warfarin therapy 
with an INR target value of between 2.5 and 3.5. All patients on warfarin therapy 
were advised to follow up monthly at local clinics for INR control.  
The primary endpoints of the study were death and reoperation. The patient follow-
up was conducted through review of the medical records, telephonic interviews or 
through home visits when necessary.  For untraceable patients, follow-up data was 
based on information recorded at the most recent hospital visit, provided that this 
visit fell within the period in which we started contacting patients. Untraceable 
patients, whose most visit was prior to our follow up period were considered lost to 
follow up and were not included in the study.  
Patients referred from other centres or provinces were particularly difficult to contact 
as the majority did not currently valid telephone numbers. This prompted us to travel 
to the Eastern Cape Province (about 1000km away), our major referring province, 
where we attended the Cecilia Makiwane and Frere hospitals to examine the 
patients’ medical records for follow-up data and phone numbers. Within the Western 
Cape Province, we travelled to distant hospitals in George and Mosselbaai (400-500 
km away) for the same reason. On one occasion the only link to a patient was their 
residential address and we successfully reached them when we travelled to their 
home 400km away. The country’s National Health Laboratory Services (NHLS) 
database, the Clinicom Western Cape Health Database and the South African 
Police Services (SAPS) were all valuable resources in tracing patients.  
Statistical analysis 
All inferential statistical analysis was performed using the JMP software application 
for Apple™ Macintosh (version 10.0.2; SAS Institute, Cary, NC, USA). All normally 
distributed continuous numerical data (confirmed by Shapiro-Wilk testing) were 
expressed as Means ± Standard Deviation and all nonparametric numerical data as 
Medians and range. The primary end-point of the study was defined as either valve 
re-operation or valve-related death in accordance with the guidelines of the Society 
of Thoracic Surgeons for reporting mortality and morbidity after cardiac valve 
interventions 58. Following the identification of patient age as a contributing variable 
affecting outcome by nominal logistic modelling, reiterative partition modelling was 
applied to identify an age-related cut point. Product-limit (Kaplan-Meier) survival 
estimates were calculated at five and ten years postoperatively for both age groups 
as well as for valve repair and valve replacement groups. A Log Rank statistic was 
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calculated to test survival homogeneity across the groups. Patients who remained 
un-reoperated and alive were censored at the end of their respective follow-up 
periods. A p-value <0.05 was accepted as confirming statistical significance. 
 
Results 
Early clinical outcome 
There was no intra-operative mortality. 30 day mortality occurred in 2 patients (3%). 
One was a 15 year old girl, followed up for 1 year at our hospital prior to her 
surgery. She presented in florid pulmonary oedema due to critical mitral stenosis 
(valve area of 0.8, peak gradient 50mmHg) and required aggressive pre-op 
resuscitation following a cardiac arrest in the ICU. Emergent salvage MVR was 
attempted but she nevertheless died 5 days later without regaining consciousness. 
The other patient died at the referring hospital in the Eastern Cape Province three 
weeks following MVrep. The cause of death was cardiac tamponade due to a large 
pericardial effusion.  
Late clinical outcome 
Late mortality 
Late mortality occurred in 9 patients (12%). One patient died from severe cardiac 
tamponade at 6 weeks following MVR shortly after emergent drainage of the 
pericardial effusion. Another patient died 3 years post surgery after he contracted 
pulmonary tuberculosis (TB), and defaulted treatment, dying as a result of TB 
complications. Another patient died from a thromboembolic stroke (CVA) nine years 
after MVR. The remaining late mortalities were all cardiac-related: three occurred in 
patients who presented with poor preoperative left ventricular functions (EF less 
than 40% in the face of severe MR). The other three patients died as a result of 
structural valve deterioration following repairs and before further surgery could be 
undertaken. 
With statistical partition modelling, an age “cut point” of 12.8 years was identified 
and the two groups (above and below 12.8 years) were analysed in terms of their 
differential outcomes. Actuarial freedom from death at 5 and 10 years for children 
over 12.8 years was 77.7% (+-9.9) and 69.1% (+-12.0) respectively, compared to 
93.6% (+-3.6) and 93.6% (+-3.6) for children under 12.8 years (p=0.03) (Figure 1). 
 




Early reoperations: There were no reoperations within 30-days of surgery. 
Late reoperations:  
 For the repairs, there were a total of 9 reoperations out of the 45 who 
underwent repairs (Table 3), giving a reoperation rate of 20% over a mean 
period of 60.87 months. The earliest reoperation was at 7 weeks in a 13 year 
old girl, due to dehisced sutures on the mitral annuloplasty ring; she had a 
MVR. Three out of the nine reoperations had documented new episodes of 
ARF infections; and two of these patients also had infective endocarditis. 
Four patients were reoperated due to structural valve deterioration. The 
remaining patient needed surgery for a persistent prolapse of the A2 
segment of the anterior mitral valve leaflet (this is the patient previously 
mentioned, who had a suture annuloplasty at the first repair). This last 
patient was the only one in our study, who underwent a second successful 
repair, at which an annuloplasty ring was used.  
 Of the three patients having commissorotomies (OMV) only, one was re-
operated after 4 years for restenosis, when a MVR was done, another was 
reoperated with MVR after 10 months due to severe MR that developed in 
the months after surgery. The third patient was lost to follow up. 
 Of the 28 patients who had MVR, three (10%) had reoperations (Table 3). 
The earliest reoperation was for a paravalvular leak 90 days after an 
emergent MVR for MS with pulmonary oedema. At initial surgery, the 
myocardium was severely inflamed, with the valve histology confirmed 
acute-on-chronic carditis. The remaining two re-operations were done for 
clotted valves at one and two years post operatively respectively. 
The actuarial freedom from reoperation for repairs was 83% (+-2.2) and 66% (+-3.4) 
at 5 and 10 years, while it was 87% (+-4.8) and 87% (+-4.8) for replacements 
(p=0.27)  
Valve-related morbidity 
Clotted valves: We had two (7%) clotted valves in the study; one patient was 13 
years old at initial MVR and the valve clotted two years later during pregnancy, with 
a concomitant cerebrovascular accident. The other patient was 8 years old at initial 
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MVR and clotted the valve one year after surgery due to poor compliance with 
anticoagulation. 
Thromboembolic cerebrovascular accident (CVA): four patients (14%) developed 
thromboembolic CVA after MVR (Table 3). None in the MVrep group developed a 
CVA; actuarial freedom from embolic CVA in the MVrep group at both 5 and 10 
years was 100%, compared to 90.2% (+-6.6) and 79% (+-12.0) for the MVR group 
at 5 and 10 years respectively (p=0.02)(Figure 3). 
Paravalvular leaks: There were two paravalvular leaks (Table 3). One patient was 
reoperated and the other had a trivial leak, managed conservatively. 
Infective endocarditis:  five patients developed infective endocarditis. Two in the 
MVrep group, both treated conservatively and three in the MVR group (Table 3), of 
which two underwent reoperation while the third was treated conservatively. 
Anticoagulation related haemorrhage: Only one patient required admission and 
blood transfusion for anticoagulation related haemorrhage (Table 3). 
No statistical significant difference was noted in the freedom from valve related 
failure and death between repairs and replacements (Fig 4). 
 
Demographics, Population Migration and Follow-up 
We achieved a 91% follow up over a median follow up period of 7.41 years (range 
0-15 years).The majority (57%) of patients in the study were from within the 
Western Cape Province, where we are situated. A significant number of patients 
(41%) were referred from the Eastern Cape Province. A further 2% were referred 
from the Northern Cape Province. Patients referred from other provinces all 
returned to their provinces after surgery. The indigent black patients made up 76% 
of all patients, while the remaining 24% were of mixed race. Females made up 66% 
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Discussion 
This study can attest to a previous study from our department by Geldenhuys et al 
59 that cellular phone penetration has had a positive impact on the follow up of 
patients in the developing world. A 91% follow up compares well to studies in 
developed nations 38 53, whilst for many studies in the developing world follow-up is 
particularly difficult. Whilst the official “cut-off” age for treatment at the RCCWMH is 
12 years old, because of the particular problems of compliance and follow-up in 
adolescent patients we prefer to “keep” our patients as long as possible, sometimes 
even operating on patients as old as 17 years being treated at our paediatric 
hospital. For this study we included all patients from the ages of birth to 17 years 
operated at RCWMCH. 
One unexpected finding in this study is the poorer outcome of surgery for children 
over 12.8 years. This is likely due to various factors, particularly late presentation to 
healthcare facilities, and poor compliance amongst teenagers. Antunes’ South 
African cohort of 1983 also showed worse for children older than 15 years having 
mitral annuloplasty for RHD, although it did not reach statistical significance 54. In 
our series the majority of children above 12.8 years were referred from distant rural 
areas of the Eastern Cape Province, where access to health care is poor. African 
cultural beliefs are also known to play a significant role in delayed presentation to 
hospital. One family in our study believed their child to be “bewitched” and as a 
result only sought medical help late in the disease process after consulting various 
traditional healers. The level of education of the parents has a significant bearing on 
how they care for their children. To illustrate, the parents of another child, who was 
failing to thrive with poor effort tolerance labelled her as merely a “weak child” and 
did not seek medical care until late in the disease process. This cultural impact on 
healthcare access has been well described by Russel et al 60. 
Thrombo-embolic strokes were seen in 14% of our valve replacement patients but in 
none of our repairs. The actuarial freedom from embolic CVA in the MVR group 
(90.2% and 79% at 5 and years respectively) compared to the absence of CVA in 
the MVrep group (p=0.02) represents a significant morbidity and potential mortality 
(one of our patients) related to MVR. Thus it is concerning that some of our patients 
fail to attend follow up visits for anticoagulation control after returning home, 
especially in the more rural areas. We know of at least two such patients with 
mechanical valves who have been lost to follow up. This raises a dilemma in the 
choice of implant for MVR in rural patients. It is well established that bioprosthetic 
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valves have a high failure rate in the young, although they are still an acceptable 
alternative in women of childbearing age 36, 61, 62. In Antunes’ study in the 1980’s in 
Johannesburg, South Africa, the survival from degeneration of bioprosthetic valves 
was only 20% at 6 years in patients younger than 20 years 36. With this in mind, we 
have only implanted mechanical valves in children, sometimes opting for a less than 
perfect repair rather than MVR if a patient is from a rural area.  
In our series the actuarial freedom from reoperation for repairs was 83% (+-2.2) and 
66% (+-3.4) at 5 and 10 years. Pomerantzeff in Brazil in 2000 had a 43% freedom 
from reoperation at 10 years 30. Skoularigis’ rheumatic mitral repair cohort (mean 
age 18 years) in Johannesburg, South Africa, in 1994 had a 75% freedom from 
reoperation at 5 years 51. Choudary in 2001 reported an Indian rheumatic mitral 
valve repair cohort (mean age 23 years) with a freedom from reoperation at 11 
years of 65% 34. Chauvaud et al. (1986) and Kalangos et al ( 2008 and 2012) from 
Europe reported a 10 year freedom from reoperations in excess of 78% up to 93% 
15, 39, 53.  
 The higher reoperation rate that we experienced among our repair group may in 
some cases be attributed to repeat episodes of ARF in the post operative period, 
and to progression of scarring in the valve leaflets. Recrudescence of ARF are due 
to the poor application of secondary prophylaxis in our setting, where access to 
healthcare is seriously compromised by socio-economic factors for the majority of 
our patients 2, 5. 
Study limitations 
The retrospective nature of our study was a limitation as for all studies of this 
nature. We were unable to obtain recent echocardiograms in all the patients at the 
time of follow-up and this at best only yields a subjective impression of the 
functional status of the valves as judged from clinical symptoms and effort tolerance 
of the patients. We run a relatively low volume unit and we could only achieve a 
follow-up of 91%. It would have been ideal to achieve a follow up of 100% when 
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Conclusions 
There was no significant difference in survival between the repairs and 
replacements. There was surprisingly poor survival among children above 12.8 
years of age at the time of surgery and this is probably due to late presentation to 
healthcare facilities, and poor compliance amongst teenagers. 
 Repair of rheumatic mitral valves should always be attempted if at all possible in 
order to avoid the complications associated with mechanical valves 
• Hopefully with the advent of the REMEDY registry we will see an 
improvement in secondary prophylaxis with a resultant reduction in the risk 
of repeated attacks of ARF and also then a reduction in the need for this 
type of surgery. 
• Ensuring timely referral of patients for surgery will be a secondary benefit of 
improved surveillance through registries. 














           
 






Table 1. Patient characteristics 






          
Females 66% 31 17 2 
Males 34% 14 11 1 
Age     
   Median      11      10.43      11.02      11.14 
   Range 4-17 5-17 4-15      10-13 
Weight (kgs)     
   Median     25    26    25 23 
   range 13-50 14-49 13-50 22-34 
Preoperative AF 3 1 2 0 
Indication for 
surgery  
    
   Pure MR 51 34 17 0 
   Pure MS 5 0 2 3 
   Mixed MR and 
MS 
20 11 9 0 
Follow-up      
   Recent 69(91%) 41 26 2 
   Not recent  7(9%) 4 2 1 
Follow up 
time(years) 
    
   Median 7.41 8 8 7.5 
   Range 0-15 0-13 0-15 6-9 
     
 































Other procedures MVR MVRep OMV 
Tricuspid 
annuloplasty  
3 3 0 
MAZE 0 1 0 
 
















CVA(stroke) 0 4 0
Prosthetic SBE 2 3 0
Clotted valves 0 2 0
Paravavular leaks 0 2 0
Reoperations 9 3 2
Anticoagulation complication 0 1 0












































































Figure 4. Freedom from Valve Related Failure/Death as a function of Mitral Valve     
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